Onkologie. 2017:11(3):144-147 | DOI: 10.36290/xon.2017.028

Thymomas and thymic carcinomas

Eva Sedláčková
Onkologická klinika VFN a 1. LF UK Praha

Thymomas and thymic carcinomas are relatively rare tumours, not often seen by medical oncologist. Article deals with epidemiology,

diagnosis, classification, therapy and dispensarisation of epitelial thymic tumours based on contemporary ESMO guidelines (1) and own 37 years experience.

Keywords: thymoma, thymic carcinoma, autoimmune diseases, maysthenia gravis, chemotherapy, radiotherapy, targeted therapy

Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sedláčková E. Thymomas and thymic carcinomas. Onkologie. 2017;11(3):144-147. doi: 10.36290/xon.2017.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Girard N, Rufini E, Marx A, et al. Thymic epithelial tumoursw: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 26(Supplement 5): v40-v55, 2015. Go to original source... Go to PubMed...
    2. de Jong WK, Blaauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy Eur J Cancer 2008; 44: 123-130. Go to original source... Go to PubMed...
    3. Kojima Y, Ito H, Hasegawa S, et al. Resected invasive thymoma with mutiple neruoendocrine neoplasia type 1. Jpn J Thorac Cardiovasc. Surg 2006; 54: 171-173. Go to original source... Go to PubMed...
    4. Carter BW, Marom EM, Detterbebeck FC. Approaching the patient with an anterior meediastíinal mass: a guide for clinicians. J Thorac Oncol 2014; 9(Suppl. 2): S102-S109. Go to original source... Go to PubMed...
    5. Marx A, Srobel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol 2014; 9: 596-611. Go to original source... Go to PubMed...
    6. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special refference to their clinical stages. Cancer 1981; 48: 2485-2492. Go to original source...
    7. Koga KI, Matsuno Y, Noguchi M, et al. A review of 79 thymomas : modifiaction of staging system and reappraisal of conventional division into invasive and noin-invasive thymoma. |Pathol Int 1994; 44: 359-376. Go to original source... Go to PubMed...
    8. Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011; 6(Suppl. 3): S1698-S1704. Go to original source... Go to PubMed...
    9. Detterbeck FC, Moran C, Huang J, et al. Which way is up? Policies and procedures forvsurgeons and pathologists regarding resection specimens of thymic malignancy. J Toracic Oncol 2011; 6(Suppl. 3): S1730-S1738. Go to original source... Go to PubMed...
    10. Omasa M, Date H, Sozu T, et al. Postoperative radiotherqapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epitelial tumours: The Japanese Association for Research on the Thymus database Study. Cancer 2015; 121: 1008-1016. Go to original source... Go to PubMed...
    11. Patel S, Macdinald OK, Nagda S, et al. Evaluation of the role of radiation therapy in the management of malignant thymoym. Int J Radiat Oncol Biol Phys 2012; 82: 1797-1801. Go to original source... Go to PubMed...
    12. Korst RJ, Bezjak A, Blackmon S, et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase |II mutiinstitutional clinical trial. J Thorac Cardivasc Surg. 2014; 147: 36-34.
    13. Yellin A, Siímansky DA, Ben-Avi R, et al. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disesase and pleuralo spread: a single institution experience. J Torac Cardiovasc Surg 2013; 145: 83-87. Go to original source... Go to PubMed...
    14. Hamaji M, Kojima F, Omasa M, et al. A meta-analysis of debulking surgery versus versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg 2015; 47: 602-607. Go to original source... Go to PubMed...
    15. Okuma Y, Salto M, Hosomi Y, et al. Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-,carboplatinor cisplatin-based chemotherapy. J Cancer Res Clin Oncol 2015; 141: 323-331. Go to original source... Go to PubMed...
    16. Sandri A, Cusumano G, Lococo F, et al. Long term resultsafter treatment for reccurtent thymoma: a multicdentric analysis.Jthorac Oncol 2014; 9: 1796-1804. Go to original source... Go to PubMed...
    17. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II triasl of pemetrexet in patients with recurrent thymoma or thymci carcinoma. J Clin Oncol 2006; 24(Suppl. 18): abstr 7079. Go to original source...
    18. Loehrer PJ, Sr, Wang W, Johnson DH, et al. Octreotid alonhe or with prednisone in patients with adavanced thymoma and thymic cearcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22:293-299. Go to original source... Go to PubMed...
    19. Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epthelial tumors. J Thorac Oncol 2014; 9(Suppl. 2): S131-S136. Go to original source... Go to PubMed...
    20. Thomas A, Rajan A, Berman A, et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015; 16: 177-186. Go to original source... Go to PubMed...
    21. Zucali PA, De Pas TM, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2014; 32 (5s Suppl): abstr 7527. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.